Loading
Life sciences · Journal article
Cancer Nanotechnology · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Natural active compounds (NACs) possess diverse anticancer activities but are often limited by poor aqueous solubility, low bioavailability, insufficient tumor selectivity, and inadequate in vivo stability. Self-assembled products from natural active compounds (SAPNACs) provide a carrier-minimized approach in which NACs directly participate in nanostructure construction, stabilization, or functional organization through non-covalent interactions or metal coordination. Unlike previous reviews that broadly discuss natural-product nanomedicine or carrier-free drug delivery, this review establishes a mechanism-oriented framework for SAPNACs by clarifying their conceptual boundaries and linking molecular features, intermolecular interactions, assembly pathways, physicochemical properties, and anticancer performance. It further distinguishes genuine SAPNACs from conventional carrier-loaded formulations and proposes a classification encompassing pure NAC assemblies, multi-NAC co-assemblies, NAC-drug assemblies, metal ion-mediated systems, protein- or nucleic acid-associated assemblies, and multicomponent hybrids. Their applications in chemotherapy, immunotherapy, phototherapy, magnetic hyperthermia, sonodynamic therapy, herbal therapeutics, and tumor microenvironment regulation are critically evaluated. Key translational barriers, including structural validation, in vivo integrity, pharmacokinetics, biosafety, reproducibility, scalable manufacturing, quality control, and regulatory classification, are also discussed. This framework provides practical criteria for the rational design, evaluation, and clinical development of SAPNAC-based cancer nanomedicines.